Navigation Links
Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder
Date:1/8/2009

Current and Emerging Drugs Will Not Surpass Vyvanse as the Clinical Gold Standard, According to a New Report From Decision Resources

WALTHAM, Mass., Jan. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians indicate there is an unmet need for a safe and effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder (ADHD) with no risk of suicidal ideation. Such a drug has potential to earn a 25 percent patient share of the drug treated adult ADHD population, according to surveyed U.S. psychiatrists. In contrast, in Europe, such an agent would earn a markedly higher patient share of 40 percent, according to surveyed European psychiatrists.

This difference in patient share likely reflects U.S. physicians' reasonably high level of satisfaction with currently-available psychostimulants, with which they have decades of clinical experience, despite their disadvantages of abuse-liability and prescribing restrictions. Conversely, European physicians have to contend with greater prescribing restrictions, fewer treatment options, and are more averse to stimulants' risk of abuse than their U.S. counterparts. As a result, physicians would greatly welcome a safer and more effective nonstimulant alternative to Eli Lilly's Strattera as a first-line therapy for adult ADHD.

The new report entitled Attention-Deficit/Hyperactivity Disorder: Emerging Therapies Fall Short of Physicians' Expectations for Safer and More-Effective Nonstimulants finds that current and emerging drugs have not yet demonstrated substantial clinical advantages over Shire's Vyvanse, Decision Resources' 2008 clinical gold standard in the treatment of ADHD. According to interviewed physicians, none of the emerging therapies represent a major innovation in ADHD treatment or offer an overwhelmingly preferable balance of efficacy, safety and convenience compared to that of currently available psychostimulants.

"With a host of generally safe and effective stimulant products already approved for ADHD which are used to treat the majority of patients, interviewed physicians have targeted a remaining need for safer and more-effective nonstimulant alternatives that are approved for ADHD, both in children and adults," said Andrea Buurma, analyst at Decision Resources.

About the Report

Attention-Deficit/Hyperactivity Disorder: Emerging Therapies Fall Short of Physicians' Expectations for Safer and More-Effective Nonstimulants is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help clients optimize their investments in drug development. Driven by quantitative and qualitative primary research, DecisionBase 2009 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. Each report provides detailed market share, patient share and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Heather Hilty                      Elizabeth Marshall
    Decision Resources                 Decision Resources, Inc.
    781-296-2536                       781-296-2563
    hhilty@dresources.com              emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Renal Physicians Association 2009 Annual Meeting
2. Medical Specialists of the Palm Beaches Selects Allscripts Electronic Health Record to Connect and Automate 85 Physicians
3. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
4. Aurora Physicians Receive National Recognition for Quality Diabetes Care
5. Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
6. Supply of board-certified emergency physicians unlikely to meet projected needs
7. Dr. Steven Liu, Founder of Ingenious Med, Recognized as a Leading Hospitalist by the American College of Physicians
8. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
9. Medscape Physician Connect Becomes Largest Online Physician Social Network with More than 100,000 Physicians
10. Scientists, Physicians, Health, and Environmental Justice Advocates to New Obama EPA Director: We Look Forward to Toxic Chemical Regulatory Reform
11. Anti-Aging Miracle Physicians Have Been Waiting for is Finally Here : Free Book Available From Natural Health News Report Reveals the Secret to Staying Young
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... With ProGlass Prism users now have the ability to ... control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position ... With ProGlass Prism users are given the tools and effects to generate a ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business ... in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Worth Hotel in Fort Worth, Texas. Nine awards are given out in five categories. ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Dr. David Mahon ... Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson ... is an online directory that recognizes local physicians and dentists who have earned high ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies ... Fibromyalgia market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global ...
Breaking Medicine Technology: